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Volumetric‐modulated arc therapy (VMAT) requires highly accurate control of multi-
leaf collimator (MLC) movement, rotation speed of linear accelerator gantry, and
monitor units during irradiation. Pretreatment validation and monitoring of these
factors during irradiation are necessary for appropriate VMAT treatment. Recently, a
gantry mounted transmission detector “Delta4 Discover® (D4D)” was developed to
detect errors in delivering doses and dose distribution immediately after treatment.
In this study, the performance of D4D was evaluated. Simulation plans, in which the
MLC position was displaced by 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 mm from the clinically
used original plans, were created for ten patients who received VMAT treatment for
prostate cancer. Dose deviation (DD), distance‐to‐agreement (DTA), and gamma
index analysis (GA) for each plan were evaluated by D4D. These results were com-
pared to the results (DD, DTA and GA) measured by Delta4 Phantom + (D4P). We
compared the deviations between the planned and measured values of the MLC
stop positions A‐side and B‐side in five clinical cases of prostate VMAT during treat-
ment and measured the GA values. For D4D, when the acceptable errors for DD,
DTA, and GA were determined to be ≤3%, ≤2 mm, and ≤3%/2 mm, respectively,
the minimum detectable errors in the MLC position were 2.0, 1.5, and 1.5 mm
based on DD, DTA, and GA respectively. The corresponding minimum detectable
MLC position errors were 2.0, 1.0, and 1.5 mm, respectively, for D4P. The deviation
between the planned and measured position of MLC stopping point of prostate
VMAT during treatment was stable at an average of −0.09 ± 0.05 mm, and all GA
values were above 99.86%. In terms of delivering doses and dose distribution of
VMAT, error detectability of D4D was comparable to that of D4P. The
transmission‐type detector “D4D” is thus suitable for detecting delivery errors dur-
ing irradiation.
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1 | INTRODUCTION
Currently, volumetric‐modulated arc therapy (VMAT), is being widely
performed.1,2 VMAT requires highly accurate control of multileaf col-
limator (MLC), rotation speed of linear accelerator gantry, and deliv-
ering monitor units during irradiation. Even small errors in these
factors would lead to significant accidents in highly precise radio-
therapy such as VMAT; therefore, patient‐specific pretreatment veri-
fication of MLC movement and gantry rotation speed are necessary
for VMAT.3,4 In addition, there exists a possibility of failure of the
linear accelerator or its control system while the patient is being
treated. Some serious accidents have already occurred in clinical
radiotherapy.5–9 In one of these accidents, MLC opened incorrectly
during intensity modulated radiotherapy for head and neck cancer,
and the patient was seriously injured.9 Owing to a hang‐up while
using the treatment planning system(TPS), the MLC control point
data, which should have been present in the treatment planning
data, were absent.9 The accident occurred when a large number of
monitor units were delivered to patients without the MLC control
point data.9 Therefore, prior patient‐specific verification is imperative
to prevent such an accident.3,4 However, according to a report from
the Netherlands in 2010, dose errors could not be detected even
after patient‐specific preverification, and they were finally detected
by in vivo dosimetry (IVD) using an electronic portal imaging device
(EPID) during treatment.10,11 Therefore, not only pretreatment verifi-
cation but also monitoring of delivering doses and dose distribution
during irradiation are necessary for an efficient performance of the
VMAT.12 In recent years, the importance of dose verification during
irradiation has been recognized.10,11 Accordingly, EPID‐based IVD is
expected to be used for dose verification during irradiation.13 In tra-
ditional IVD, thermoluminescent dosimeter and diode detector
placed on the surface of the patient’s body have been used for dose
verification during irradiation.13 However, these dosimeters do not
seem to be suitable for IVD of VMAT that requires complex dose
distribution and steep dose gradient.13 Furthermore, real‐time dose
monitoring is impossible for IVD using EPID because IVD using EPID
requires a recalculation of the doses monitored during treatment.
For the precise detection of delivery errors during irradiation in
VMAT, a gantry‐mounted transmission detector was developed.
Gantry‐mounted transmission detectors allow monitoring of deliver-
ing doses and dose distribution during irradiation immediately after
treatment. Errors can be automatically detected immediately after
treatment by comparing the dose monitored by the transmitting
detector with the planned dose. Therefore, these systems have an
advantage in the detection of delivery errors during irradiation dose
monitoring and have been applied clinically.14,15
The purpose of this research is to investigate the possibility of
detecting errors during treatment by performing basic experiments
that create an error plan for the stop position of MLC using a
gantry‐mounted transmission detector. This study was conducted
based on the assumption that a systematic error occurred owing to
the installation position error of the leaf offset during MLC adjust-
ment. In this study, we compared the error detection capabilities of
the gantry‐mounted transmission detector used for monitoring dur-
ing treatment and a three‐dimensional detector used for pretreat-
ment patient quality assurance (QA). If the error detection
capabilities of both the detectors are verified to be comparable, the
gantry‐mounted transmission detectors can be used independently
and will be useful in clinical practice.
2 | MATERIALS AND METHODS
2.A | Material
In this study, we used the Delta4 Discover (D4D) system (ScandiDos
AB, Uppsala, Sweden) as the monitoring system to detect errors in
dose and MLC position during treatment as well as delivery errors
during irradiation. This system consists of Delta4 Phantom + (D4P)
(ScandiDos AB, Uppsala, Sweden) used for patient‐specific preverifi-
cation and the D4D gantry‐mounted transmission detector.
The linear accelerator used was a TrueBeam (Millennium 120
MLC 5 mm leaf) (Varian Medical Systems, California, USA), and
10X energy was applied. To ensure the output stability, the output
coefficient of variation of the output measurement of weekly QA
during the data collection period was calculated. The coefficient of
variation of the output dose was found to be stable at 0.19% in
the weekly QA dose control using the ionization chamber. The cal-
culated dose of TPS was obtained using Eclipse version 11.0 (Var-
ian Medical Systems, California, USA) based on the anisotropic
analysis algorithm.
2.A.1 | Delta4 discover
The very thin, disk‐shaped main unit with a diameter of 790 mm and
a thickness of approximately 22 mm measured from the front of the
collimator, was designed to fit inside the TrueBeam laser guard. The
D4D consisted of 4,040 p‐type diode detectors with a diameter of
1.0 mm and a thickness of 0.1 mm. Regarding the detector arrange-
ment, the elements were separated by approximately 1.5 mm, in the
X direction (parallel direction along the MLC trajectory) and by
3.0 mm approximately in the Y direction (direction perpendicular to
the MLC trajectory). This arrangement is equivalent to 2.5 mm and
5.0 mm intervals in the X and Y directions, respectively, converted
to the isocenter plane; the detector covered 195 × 250 mm on the
isocenter. The overall thickness, including the detector cover, was
5.5 cm, and the source‐to‐detector distance was 604 mm. In addi-
tion, as a transmission type detector, it has a small effect on the
beam transmission and surface dose.16
2.A.2 | Delta4 phantom +
D4P consists of 1,069 diodes on two orthogonal boards and a p‐
type diode detector with the same 1.0 mm diameter as in D4D. In
the central area (60 mm × 60 mm), the detectors are placed at
5 mm intervals, while on the periphery, they are at placed 10 mm
intervals. They cover a total area of 200 mm × 200 mm. These
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detectors were cased inside an acrylic cylindrical phantom that had a
diameter of 22 cm and length of 40 cm.17
2.B | Treatment planning
2.B.1 | Original plan
In this study, new plans (original) for evaluation were created based
on the VMAT plans used in clinical practice for ten prostate cancer
patients (2‐arc plan with 181°–179° clockwise (CW) rotation and
179°–181° counterclockwise (CCW) rotation). The original plans
were changed to 1‐arc plans (181°–179° CW rotation) without
changing the optimization parameters. The collimator angle was 30°.
The number of control points of MLC of the plan created by the
treatment planning device was 178.
2.B.2 | Simulated plan for detecting errors during
treatment
Six types of errors were intentionally introduced to the original plans
considered in this study. The simulation plan for detecting errors
during treatment consisted of the MLC of all the control points dis-
placed from the B‐side (X1 side) to the A‐side (X2 side) by 0.5, 1.0,
1.5, 2.0, 2.5, and 3.0 mm from the original plan. Figure 1 shows a
schematic diagram of the MLC stop position in the original plan and
the MLC stop position where the MLC stop positions on the A‐side
and B‐sides are displaced by 3.0 mm.
2.C | Method
First, the D4P was setup at the isocenter using the treatment room
laser. Next, 100MU irradiation was performed from a gantry angle
of 0° and 90° in a 10 cm × 10 cm irradiation field, and the profile
was confirmed using the software provided with D4P. Based on the
profile calculated by TPS, the TrueBeam couch was moved in
0.1 mm increments to a position where they matched best, and the
D4P was re‐setup. Figure 2 shows the procedure of D4D measure-
ment. As D4D is a fluence measuring transmission detector, the dose
is measured by synthesizing the dose as measured by D4P.18
2.C.1 | Evaluation of reproducibility
As D4D is a gantry‐mounted transmission detector, the measure-
ment value may vary depending on the mounting position. First, the
reproducibility of the measurement due to the accuracy of the
detector's attachment to the gantry is evaluated. D4D then obtains
the measurement results based on the reference measurements col-
lected at the same time as D4P. Thereby, we evaluate the repro-
ducibility of the D4P setup.
Evaluation of D4D reproducibility in the same setup (D4D
mounting reproducibility)
The D4D mounting accuracy reproducibility was evaluated for one
prostate cancer treatment. First, D4P was set up to measure the
dose distribution of the original plan and six simulated plans. Next,
as shown in Figure 2, the reference measurements were performed
using D4P and D4D. Further, using D4D only, we have measured
the dose distribution of the original plan and the six types of simu-
lated plans. The measurements in this study were performed first,
F I G . 1 . Schematics of MLC same‐
direction sifts. (a) Schematic of the original
MLC position. (b) Schematic of the stop
position of A‐side and B‐side MLC
displaced 3.0 mm from B‐side to A‐side
direction.
F I G . 2 . Procedure of D4D measurement. Combine D4P and D4D
to measure the reference measurement using the "synthetic mode".
Next, the fluences are converted into doses by directly measuring
using D4D. * Reference measurement of this process should be
performed for all dose verification cases.
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with D4P alone; then, D4D was mounted and measured. This is
defined as one set of measurement. D4D was dismounted and
mounted before each set of measurements. To measure the D4D
mounting repeatability, the mount‐dismount process was repeated
ten times.
Evaluation of reproducibility of D4P setup (Reproducibility of
reference measurement)
To evaluate the reproducibility of the D4P setup, we have used the
original plan for one prostate treatment used in the evaluation of
D4D reproducibility, and six types of simulated plans. D4P and D4D
were used to re‐setup ten times on another day instead of the same
day, and the dose distribution was measured.
2.C.2 | Evaluation of VMAT for ten prostate cancer
patients
The setup of ten patients’ prostate treatment plans was measured
similar to the evaluation of the reproducibility of the D4D setup.
The process in Figure. 2 was repeated for each case and the dose
distribution of D4P and D4D was measured once.
2.C.3 | Evaluation criteria
To evaluate the methods of 2.C.1‐2.C.2, dose deviation (DD),
distance‐to‐agreement (DTA), and gamma index analysis (GA) were
used for D4P and D4D reproducibility. The evaluation criteria
observed were DD at 3%, DTA at 2 mm, GA at 3 %/2 mm, with the
threshold set at 10%.4 The variation was evaluated at a 95% confi-
dence interval (1.96 standard deviations). The GA was performed
with a global normalization in the absolute doses. For the evaluation
of VMAT for ten prostate cancer patients, we have performed a sta-
tistical test for significant differences between the original and simu-
lated plans, using Welch's t‐test. A p‐value of 0.05 was used; after
performing Bonferroni correction considering multiple comparisons,
a p‐value less than 0.007 was considered statistically significant.
2.D | Variation in MLC stop position and GA of
prostate VMAT clinical data using D4D
Rangel et al. reported a less significant impact on delivery errors
owing to random errors compared to systematic errors in MLC.19
Therefore, the evaluation of the basic error detection capability in
this study was performed under the assumption that systematic
errors occurred due to leaf offset placement errors during MLC
adjustment. However, it is also important to investigate the MLC
random errors. Therefore, we compared the deviations between the
planned and measured values of the MLC stop positions A‐side and
B‐side of the 2‐arc plan in five clinical cases of prostate VMAT and
measured the GA values. The number of treatments in one case ran-
ged from 39 to 40; a total of 396 A‐side and B‐side MLC stop posi-
tions were recorded. The A‐side and B‐side deviations between the
average of the MLC stop positions in the treatment plan and the
average of the MLC stop position measured at each treatment were
calculated. The GA value was 3%/2 mm, and the threshold was 10%.
The GA was performed with a global normalization in the absolute
doses. The average value and standard deviation (1SD) were calcu-
lated from the average value for each 1‐arc plan.
3 | RESULTS
3.A | Evaluation of D4D reproducibility in the same
setup (D4D mounting reproducibility)
Figure 3 shows the pass rates of DD, DTA, and GA obtained by
measuring the dose distribution of the original plan and each simu-
lated plan, repeated ten times for an evaluation of the repeatability
of the D4D in the same setup.
3.A.1 | DD
Figure 3a shows that, when the MLC position error exceeds 1.5 mm,
the D4D DD pass‐ratio exceeds that of D4P, and this tendency
increases as the MLC position error increases. The maximum pass‐
ratio of D4P and D4D was 95.4% and 95.0%, respectively, when the
MLC position error was 1.0 mm. The minimum pass‐ratio of D4P
and D4D was 69.8% and 77.6% at 3.0 mm, respectively, and the
D4D minimum pass‐ratio was 7.8% higher than that for D4P. The
average values of the pass‐ratio variation of the original plan and the
MLC position error simulation plan were ± 0.8% for D4P and ± 1.3%
for D4D. Evidently, the variation was smaller for D4P compared to
that for D4D.
3.A.2 | DTA
Figure 3b shows that, when the MLC position error exceeds 0.5 mm,
the value of D4D becomes higher than of D4P, and the tendency is
similar to that of DD. The maximum pass‐ratio was 97.7% of the
original plan in the case of D4P and 97.5% in the case of MLC posi-
tion error of 0.5 mm in the case of D4D. The minimum pass‐ratio of
D4P and D4D was 80.5% and 87.1%, respectively, at 3.0 mm, and
the D4D minimum pass‐ratio was 6.6% higher than that for D4P.
The average values of the pass‐ratio variation of the original plan
and the MLC position error simulation plan were ± 0.9% for D4P
and ± 1.2% for D4D. Evidently, the variation was smaller for D4P
compared to that for D4D.
3.A.3 | GA
Figure 3c shows that, when the MLC position error exceeds 1.0 mm,
the value of D4D becomes higher than of D4P, similar to DD and
DTA. The maximum pass‐ratio of D4P and D4D was 100.0% when
the original plan and the MLC position error were 0.5 mm. The mini-
mum pass‐ratio of D4P and D4D was 85.7% and 89.8%, respec-
tively, at 3.0 mm, and the D4D minimum pass‐ratio was 4.2% higher
than that for D4P. The average values of the pass‐ratio variation of
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the original plan and the MLC position error simulation plan were ±
0.5% for D4P and ± 0.8% for D4D. Again, the variation was evi-
dently smaller for D4P compared to that for D4D.
3.B | Evaluation of reproducibility of D4P setup
(Reproducibility of reference measurement)
Figure 4 shows the DD, DTA and GA pass‐ratios of evaluation of
the reproducibility of the D4P setup. All these pass‐ratios indicated
a similar trend as evaluation of D4D reproducibility in the same
setup (D4D mounting reproducibility). The differences from the eval-
uation of D4D reproducibility in the same setup (D4D mounting
reproducibility) are shown below.
3.B.1 | DD
Figure 4a shows that the D4D DD pass‐ratio exceeds that of D4P
when the MLC position error exceeds 1.5 mm. The maximum pass‐
ratios of D4P and D4D were 95.5 and 94.6%, respectively, when
the MLC position error was 1.0 mm. The minimum pass‐ratios of
D4P and D4D were 70.2% and 77.9% at 3.0 mm, respectively, and
the minimum pass‐ratio for D4D was 6.7% higher than that for D4P.
The average values of the pass‐ratio variation of the original plan
and the MLC position error simulation plan were ± 1.2% for D4P
and ± 1.5% for D4D. Evidently, the variation for D4P was smaller
than that for D4D. Compared to the evaluation of D4D reproducibil-
ity in the same setup (D4D mounting reproducibility), the minimum
pass‐ratio for D4P became higher, the maximum pass‐ratio for D4D
was 94.6%, and the minimum pass‐ratio was smaller at 76.9%. In
addition, both D4P and D4D showed higher variability.
3.B.2 | DTA
Figure 4b shows that the value of D4D becomes higher than that of
D4P when the MLC position error exceeds 0.5 mm, and the ten-
dency is similar to that of DD. The maximum pass‐ratio was 97.7%
of the original plan for D4P and 97.6% for MLC position error of
0.5 mm in the case of D4D. The minimum pass‐ratios for D4P and
D4D were 80.6% and 87.2%, respectively, at 3.0 mm, and the mini-
mum pass‐ratio for D4D was 6.6% higher than that for D4P. The
average values of the pass‐ratio variation of the original plan and the
MLC position error simulation plan were ±0.8% for D4P and ±0.9%
for D4D. The variation for D4P was smaller than that for D4D.
Compared to the evaluation of D4D reproducibility in the same
F I G . 3 . Evaluation of D4D reproducibility in the same setup (D4D
mounting reproducibility). (a) DD: the horizontal axis shows the D4P
pass‐ratio, and the vertical axis shows the D4D pass‐ratio. The line
connecting the values where D4P and D4D are equal is defined as
the reference line. (b) DTA: the horizontal axis shows the D4P pass‐
ratio, and the vertical axis shows the D4D pass‐ratio. (c) GA: the
horizontal axis shows the D4P pass‐ratio, and the vertical axis shows
the D4D pass‐ratio.
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setup (D4D mounting reproducibility), the variability of both D4P
and D4D was small.
3.B.3 | GA
Figure 4c shows that the value of D4D exceeds that of D4P when the
MLC position error exceeds 1.0 mm, similar to DD and DTA. The max-
imum pass‐ratio for D4P and D4D was 100.0% when the original plan
and the MLC position error were 0.5 mm. The minimum pass‐ratios
for D4P and D4D were 85.6% and 89.3%, respectively, at 3.0 mm, and
the minimum pass‐ratio for D4D was 3.7% higher than that for D4P.
The average values of the pass‐ratio variation of the original plan and
the MLC position error simulation plan were ± 0.4% for D4P and ±
0.8% for D4D. Similarly, the variation for D4P was evidently smaller
than that for D4D. Compared to the evaluation of D4D reproducibility
in the same setup (D4D mounting reproducibility), the minimum pass‐
ratio of D4D became smaller. Additionally, the variation was almost
the same for both D4P and D4D.
3.C | Evaluation of VMAT for ten prostate cancer
patients
The DD, DTA, and GA pass‐ratios of evaluation of VMAT for ten
prostate cancer patients are shown in Figure 5. These pass‐ratios
tend to be smaller than the evaluation of D4D reproducibility in the
same setup (D4D mounting reproducibility) and the evaluation of the
reproducibility of D4P setup (Reproducibility of reference measure-
ment). Additionally, the variability was higher for both D4P and
D4D. The differences from the evaluation of D4D reproducibility in
the same setup (D4D mounting reproducibility) and evaluation of the
reproducibility of D4P setup (Reproducibility of reference measure-
ment) are shown below.
3.C.1 | DD
Figure 5a shows that the pass‐ratio of D4D DD exceeds that of
D4P when the MLC position error exceeds 1.5 mm, and this ten-
dency increases as the MLC position error increases. When the MLC
position error was 1.0 mm, the maximum pass‐ratios for D4P and
D4D were 94.5 and 93.2% respectively. The minimum pass‐ratios of
D4P and D4D were 68.6% and 74.2% at 3.0 mm, respectively, and
the minimum pass‐ratio for D4D was 5.6% higher than that for D4P.
The average values of the pass‐ratio variation of the original plan
F I G . 4 . Evaluation of reproducibility of D4P setup (Reproducibility
of reference measurement). (a) DD: the horizontal axis shows the
D4P pass‐ratio, and the vertical axis shows the D4D pass‐ratio. The
line connecting the values where D4P and D4D are equal is defined
as the reference line. (b) DTA: the horizontal axis shows the D4P
pass‐ratio, and the vertical axis shows the D4D pass‐ratio. (c) GA:
the horizontal axis shows the D4P pass‐ratio, and the vertical axis
shows the D4D pass‐ratio.
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and the MLC position error simulation plan were ±5.0% for D4P and
±4.9% for D4D. The variation for D4D was smaller than that for
D4P. The maximum and minimum pass‐ratio D4P and D4D were
smaller than the evaluation of D4D reproducibility in the same setup
(D4D mounting reproducibility) and evaluation of reproducibility of
D4P setup (Reproducibility of reference measurement). In addition,
both D4P and D4D showed higher variability.
3.C.2 | DTA
Figure 5b shows that the value for D4D was higher than that for
D4P when the MLC position error exceeded 0.5 mm, and the ten-
dency was similar to that of DD. The maximum pass‐ratio was
96.9% of the original plan for D4P and 96.8% for MLC position error
of 0.5 mm for D4D. The minimum pass‐ratios for D4P and D4D
were 83.0% and 85.9%, respectively, at 3.0 mm, and the D4D mini-
mum pass‐ratio was 2.9% higher than that for D4P. The average val-
ues of the pass‐ratio variation of the original plan and the MLC
position error simulation plan were ±3.4% for D4P and ±3.0% for
D4D. The variation for D4D was smaller than that for D4P. The min-
imum pass‐ratio for D4P was greater than evaluation of D4D repro-
ducibility in the same setup (D4D mounting reproducibility) and
evaluation of the reproducibility of D4P setup (Reproducibility of
reference measurement).
3.C.3 | GA
Figure 5c shows that the value for D4D was higher than that for
D4P when the MLC position error exceeded 1.0 mm, similar to DD
and DTA. The maximum pass‐ratio for D4P and D4D was 100.0%
when the original plan and the MLC position error were 0.5 mm.
The minimum pass‐ratios for D4P and D4D were 82.9% and 87.1%,
respectively, at 3.0 mm, and the minimum pass‐ratio for D4D was
4.2% higher than that for D4P. The average values of the pass‐ratio
variation of the original plan and the MLC position error simulation
plan were ±3.9% for D4P and ± 3.2% for D4D. Similarly, the varia-
tion for D4D was evidently smaller than that for D4P. The maximum
pass‐ratios were the same for both D4P and D4D. However, varia-
tion was observed at 0.5 mm.
3.C.4 | Statistical significance test
We performed a statistical significance test to evaluate the differ-
ences between the simulated plan and the original D4D plan using
F I G . 5 . Evaluation of VMAT for ten prostate cancer patients. (a)
DD: the horizontal axis shows the D4P pass‐ratio, and the vertical
axis shows the D4D pass‐ratio. The line connecting the values
where D4P and D4D are equal is defined as the reference line. (b)
DTA: the horizontal axis shows the D4P pass‐ratio, and the vertical
axis shows the D4D pass‐ratio. (c) GA: the horizontal axis shows the
D4P pass‐ratio, and the vertical axis shows the D4D pass‐ratio.
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Welch's t‐test on DD, DTA, and GA. Table 1 lists the p‐values. The
D4D p‐value for comparing DD was p = 0.194 when the MLC posi-
tion error was 1.5 mm; the p‐value of DTA for the MLC position
errors of 0.5 mm and 1.0 mm were p = 0.397 and p = 0.175, respec-
tively; and the p‐value of GA with the MLC position error at 0.5 mm
and 1.0 mm, showed no significant differences between the
p = 0.168 and p = 0.084 values. When the positional error of MLC
was 0.5 and 1.0 mm, the pass rate with DD was higher than that in
the original plan, with a significant difference (p < 0.007). When the
positional error of MLC was 2.0, 2.5, and 3.0 mm, the pass rate with
DD was lower than that in the original plan, with a significant differ-
ence (p < 0.007). DTA and GA showed a significant difference at
p < 0.007 when the MLC position error from the original plan
increased from 1.5 mm. When DD, DTA and GA parameters were
used, the detection of MLC error was 2.0 mm for DD and 1.5 mm
for DTA and GA.
Furthermore, the statistical test was performed for D4P. For
D4P, MLC error detection was 2.0 mm for DD, 1.0 mm for DTA,
and 1.5 mm for GA.
3.D | Variation in MLC Stop Position and GA of
Prostate VMAT Clinical Data Using D4D
According to the data listed in Table 2, the variation of MLC stop-
ping position of prostate VMAT (A‐side and B‐side) was calculated.
The deviation from the measured value was stable at an average of
−0.09 ± 0.05 mm (maximum +0.17 ± 0.07 mm, minimum
−0.46 ± 0.03 mm) in all five cases, and all the GA values were above
99.86%. The variation of the GA value was as small as ±0.11%.
4 | DISCUSSION
In this study, we evaluated the ability of the D4D for detecting MLC
position error, measuring the dose distribution of the original plan
and simulated plan. As EPID in a previous study reportedly detected
an MLC error of 3 mm during treatment, we evaluated whether the
gantry‐mounted transmission detector used in this study had the
same order of detection capability.20,21 First, we assessed the repro-
ducibility of the D4D setup for the same day. To ensure the output
stability, the output coefficient of variation of the output measure-
ment of weekly QA during the data collection period was calculated.
The variation coefficient of the output dose of the linear‐accelerator
device used in this study was found to be stable at 0.19% in the
weekly QA dose control using an ionization chamber. The one daily
short‐term reproducibility output coefficient of variation was 0.01%.
In the previous reports, the short‐term reproducibility of ten D4P
measurements was 0.1% (1SD) and the long‐term stability was 0.5%
(1SD).17 For DD, DTA, and GA measured by D4D, the variation in
the pass‐ratio displayed a tendency to increase as the MLC position
error increased. However, the variation in the pass‐ratio for DD,
DTA, and GA of D4P for each plan did not change significantly. The
possible explanation of these results could be the uncertainties in
the setup of the D4P and D4D dose verification systems, and the
uncertainties of the D4D and D4P system mechanical features. Since
D4D was mounted and dismounted for each measurement, the
uncertainties due to the D4D mounting/demounting were a poten-
tial reason for the setup error. Next, we considered the uncertainty
due to the mechanical accuracy of the D4D and D4P systems.
Regarding the mechanical accuracy of the D4D and D4P systems,
the difference in the geometric arrangement between D4D and D4P
could induce the difference in the detector arrangement, and affect
the rotation of the collimator. In D4D, detectors are mounted on the
gantry head, therefore, rotated along with the collimator. In contrast,
detectors of D4P, as placed on the treatment couch, do not rotate
with the rotation of the collimator. Further, rotating the collimator
may affect the D4D and D4P dose verification results. In addition,
the effect of the detector spacing is considered. The D4P detectors
are placed at a distance of 5.0 mm between the elements, within a
60 mm × 60 mm area at the center of each board, and 10.0 mm
between the elements outside the center area of 60 mm × 60 mm.
The D4D detectors are arranged at intervals of 2.5 mm and 5.0 mm
in the X and Y directions, respectively, in terms of the isocenter. As
a result, D4D exhibits a better resolution than D4P. The display of
D4D dose distribution shows the dose changes at the isocenter, not
on the detector surface of D4D. These complex factors such as
TAB L E 1 Comparison of p‐value that all MLC position error simulation plans can detect in ten plans.
Evaluation method Device
MLC error (mm)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
DD D4P 1.000 <0.001* <0.001* 0.419 <0.001* <0.001* <0.001*
D4D 1.000 <0.001* <0.001* 0.194 0.001* <0.001* <0.001*
DTA D4P 1.000 0.528 0.003* <0.001* <0.001* <0.001* <0.001*
D4D 1.000 0.397 0.175 0.001* <0.001* <0.001* <0.001*
GA D4P ‐ 0.168 0.018 0.001* <0.001* <0.001* <0.001*
D4D ‐ 0.168 0.084 <0.001* <0.001* <0.001* <0.001*
Statistical tests were performed on the significance of the original design and the simulated design (MLC position error 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 mm)
using Welch's t‐test. Both D4P and D4D were evaluated. Using a Bonferroni correction to account for multiple comparisons using 0.05, a p‐value was
considered to be statistically significant when it was less than 0.007.
*Statistically significant (p < 0.007), ( ‐ ) incalculable because D4P and D4D are 100%.
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detector spacing, detector surface, and isocenter surface dose distri-
bution affect D4D dose distribution. The D4P provides the point
dose difference in a 3D position around the isocenter, whereas the
D4D shows the errors in 2D fluence. D4P shows the measurement
results of a single unit. As D4D of a single unit cannot be measured,
a dose distribution based on the measurement results of the original
D4P plan is used to compute D4D. Therefore, the measurement
results of D4D are probably affected by the uncertainty of the mea-
surement results of D4P. Additionally, since the dose distribution of
D4D is obtained by calculations based on the MLC position error of
0 mm of the D4P original plan, the error was amplified as the MLC
position error increased, so the variation of the pass‐ratio was
expected to increase.
We now explain why the pass rate of the MLC position error of
0.5 mm was higher than the original plan of DD. The setup of the
D4P in this study comprised an irradiation field created by 10 cm ×
10 cm jaws, and the dose profile was confirmed by the software
attached to the D4P. Based on the profile calculated by the TPS, the
treatment couch was moved to the position where the two profiles
matched best by 0.1 mm, and the D4P was re‐setup. However, we
believe that there was a small difference between the center posi-
tion of the MLC and the jaws, as well as between the sagging of the
gantry and the shift of the gantry rotation center. It is considered
that these factors were complicatedly interconnected; thus, the pass
rate of the MLC position error of 0.5 mm was higher than that of
the original plan. The MLC position error plan in this study is the
one in which the MLC stop position was systematically moved at all
MLC control points. Therefore, the entire dose distribution shifted
systematically. In particular, when the steep dose gradient area
shifted systematically, this induced a significant effect on DD. It is
conceivable that DD overestimated the error because it shows a
considerable dose difference with a small positional error in the area
where the dose gradient is steep. Because DTA is useful for detect-
ing displacement in areas with steep dose gradients, we consider
that the effect of the difference in the pass‐ratio between the origi-
nal plan and the plan simulated MLC position error was small. Next,
the effect of the stop position error of MLC was not detected
because GA is a parameter that simultaneously detects the dose dif-
ference, and the position error.22
Next, the evaluation of reproducibility of the D4P setup is con-
sidered. In addition to the evaluation of D4D reproducibility in the
same setup, the re‐setup of D4P also has an effect. The DD of D4P
variation with a 95% confidence interval (1.96 standard deviations),
the evaluation of the setup reproducibility of the reference D4P data
was ±0.7% to ±1.7%. This value showed an increase in the variation
due to the D4P setup error in the evaluation of the D4D setup
reproducibility, on the same day. DTA and GA showed the same ten-
dency as DD concerning the variation due to the D4P setup error.
The evaluation of D4D reproducibility in the same setup, and the
evaluation of setup reproducibility of D4P data as a reference, are
important items of reproducibility when introducing D4P and D4D
as reported by Li G. et al.23
Finally, we considered the evaluation of VMAT in ten patients
with prostate cancer. A Welch’s t‐test for the original plan and each
simulated plan in D4D indicated that DD showed no significant dif-
ference when the MLC position error deviated by 1.5 mm from the
original plan. This is probably because the MLC position error of
1.5 mm and the average value of the original plan DD became equal.
DD showed a significant difference when the MLC position error
was 2.0 mm or more. However, DTA and GA, parameters for
TAB L E 2 Variation in MLC Stop Position and GA of Prostate
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The average and 1SD of MLC stop position variation (A‐Side and B‐Side)
of prostate VMAT clinical data by D4D were calculated. The average and
1SD of the GA of each 1arc plan were calculated.
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evaluating position information, showed significant differences with
MLC position errors of 1.5 mm or more. The error detection accu-
racy of DD is unstable in the MLC position error plan; it was sug-
gested that errors could be detected correctly by using DTA and GA.
Therefore, in clinical use, the value of DTA and GA should be regarded
as more important than the value of DD. In the linear accelerator used
in this study, MLC adjustment is performed periodically. During the
periodic MLC adjustment, systematic errors due to leaf offset mount-
ing position errors may lead to accidents. Therefore, we assumed that
the systematic error caused by the position error of the leaf offset
during the MLC adjustment occurred in this study.
Rangel et al. reported a less significant impact on delivery errors
owing to random errors compared to systematic errors in MLC,19
and in the present study, the MLC stopping position during treat-
ment between 39 and 40 days of the five prostate VMAT clinics
was confirmed to be up to ± 0.07 mm at 1 SD. For random errors, it
was small and stable. The GA value was 99.93 ± 0.30% at a maxi-
mum of −0.46 ± 0.03 mm, even if the amount of error was large
compared to the systematic error of the MLC. Our results suggest
that the variability of the GA value is reflected in the magnitude of
error when the MLC systematic error is large. However, since it
greatly exceeded the standard GA value of 95% stated in the AAPM
guideline,4 it was considered that the fluctuation was within the
standard preverification criteria. Therefore, the results of the five
cases of prostate VMAT in the present study suggest that the
impact of random errors on delivery errors is significantly less than
that of systematic errors.
The UK guidelines state that error detection with the same (or bet-
ter) accuracy as an EPID system can be considered useful in IVD.13
Liang et al. reported a minimum detectable MLC position error of
2.0 mm for D4P and 3.0 mm for EPID based on receiver operating
characteristic analysis of GA 2%/2 mm for head and neck VMATs.20 In
addition, Young et al. reported a study of MLC position error in pros-
tate VMAT using EPID; using the combination of Elekta Synergy and
in‐house software the MLC position error was 7.0 mm to below the
GA of 3%/3 mm 90%, and the MLC position error is 3.0 mm below
the GA of 2%/2 mm 90%.21 In addition, Arumugam et al. examined the
MLC position error of prostate VMAT using D4P, and reported that a
GA standard of 2%/2 mm could detect an MLC position error of
2.0 mm or more by a significant difference test.24 Although it is diffi-
cult to directly compare the present study with these previous studies
because the situation is different from these previous studies, the
MLC position error was detectable at 1.5 mm under our limited condi-
tions. In this study, the significant differences between the D4D and
D4P with GA criteria of 3%/2 mm were 1.5 mm. However, statistical
testing is not a method for pass/fail evaluation with clinical data. For
clinical data pass/fail, as mentioned earlier, the recommended evalua-
tion criteria for TG218 of the AAPM (set based on 3%/2mm at 10%
dose threshold) and a certain gamma pass rate (95%) would be
selected.4 When comparing the two detectors (D4D and D4P), it is
important to determine the level of MLC bank offset at which each
detector will fail the gamma ray pass rate. This study aimed to deter-
mine the level of MLC bank offset at which each of the two detectors
(D4D and D4P) would lead to failure of the gamma pass rate when
comparing the two detectors. D4P generally yielded failed results at
lower leaf bank offset values than those of D4D, suggesting that D4D
is a more sensitive device. Assuming a 95% pass rate, some plans
passed with D4D but failed with D4P at leaf offsets of 1.5 and 2 mm.
The user should determine whether D4D is sensitive enough for gen-
eral use after evaluating the data based relevant guidelines. The UK
guidelines do not specify the procedure to assess the accuracy of the
system or the indicators that must be used.13 Therefore, we believe
that this study contains useful information for D4D and D4P users.
Furthermore, MLC position error can be detected by D4D alone, and
we can expect its application in the detection of delivery errors during
irradiation.
Assuming that D4D is used for the detection of delivery errors
during irradiation, it is possible to accurately detect errors of the lin-
ear accelerator alone since the output dose distribution emitted from
the linear accelerator is directly observed. In contrast, when EPID is
used, the dose distribution of radiation penetrated through the
patient is measured, the effects of body shape change, and patient
setup are included. Therefore, it is challenging to evaluate error
detection only for the linear accelerator alone.
A 2010 report from the Netherlands highlighted the importance of
dose verification during treatment.10,11 Among the MLC positional
errors that occur during VMAT and IMRT treatment, this study shows
that systematic shifts in both MLC banks can be used to detect deliv-
ery errors during irradiation at a constant level. In this study, error
detection analysis was performed on the prostate as it is considered to
have the least intensity modulation among the sites.4 However, addi-
tional studies are required for more detailed detection of errors during
irradiation, involving other sites such as head and neck cases.
5 | CONCLUSION
In this study, we examined the suitability of D4D in detecting MLC
position error. It was found that D4D can detect delivery errors dur-
ing irradiation. D4D has almost the same detection power as D4P
and can detect MLC position errors of 1.5 mm or more using DTA
or GA. In conclusion, a transmission‐type detector can be suitable
for the detection of delivery errors during irradiation.
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